Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stéphanie Poulain

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Hematology/Oncology Clinics of North America|September 8, 2018
Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and BeyondMarion Magierowicz, Cécile Tomowiak, Xavier Leleu, et al.
Current Oncology Reports|February 27, 2019
How Recent Advances in Biology of Waldenström's Macroglobulinemia May Affect Therapy StrategyMarine Baron, Laurence Simon, Stéphanie Poulain, et al.
Presse Medicale (Paris, France : 1983)|August 25, 2019
[Waldenström macroglobulinaemia]Cécile Tomowiak, Stéphanie Poulain, Céline Debiais, et al.
Leukemia & Lymphoma|December 16, 2006
JAK2 V617F mutation is absent in chronic lymphocytic leukemiaStéphanie Poulain, Maud Merchez, Agnès Daudignon, et al.
Haematologica|May 30, 2008
The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or lessStéphanie Poulain, Isabelle Dervite, Xavier Leleu, et al.
Leukemia & Lymphoma|June 20, 2007
Is ZAP-70 expression stable over time in B chronic lymphocytic leukaemia?Stéphanie Poulain, Caroline Benard, Agnès Daudignon, et al.
Expert Review of Hematology|October 31, 2023
New developments in the diagnosis and characterization of Waldenström's macroglobulinemiaRamón García-Sanz, Zachary R Hunter, Stéphanie Poulain, et al.
Clinical Case Reports|March 21, 2022
Profuse telangiectasias in an immunocompetent patient misleading presentation revealing a hepatosplenic-Tγδ-cell lymphomaAva Diarra, Benjamin Carpentier, Romain Dubois, et al.
Leukemia Research|April 28, 2009
SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemiaStéphanie Poulain, Marjan Ertault, Xavier Leleu, et al.
Leukemia Research|December 5, 2009
Increased trisomy 12 frequency and a biased IgVH 3-21 gene usage characterize small lymphocytic lymphomaAgnès Daudignon, Stéphanie Poulain, Pierre Morel, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Hematology/Oncology Clinics of North America|September 8, 2018
Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and BeyondMarion Magierowicz, Cécile Tomowiak, Xavier Leleu, et al.
Current Oncology Reports|February 27, 2019
How Recent Advances in Biology of Waldenström's Macroglobulinemia May Affect Therapy StrategyMarine Baron, Laurence Simon, Stéphanie Poulain, et al.
Presse Medicale (Paris, France : 1983)|August 25, 2019
[Waldenström macroglobulinaemia]Cécile Tomowiak, Stéphanie Poulain, Céline Debiais, et al.
Leukemia & Lymphoma|December 16, 2006
JAK2 V617F mutation is absent in chronic lymphocytic leukemiaStéphanie Poulain, Maud Merchez, Agnès Daudignon, et al.
Haematologica|May 30, 2008
The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or lessStéphanie Poulain, Isabelle Dervite, Xavier Leleu, et al.
Leukemia & Lymphoma|June 20, 2007
Is ZAP-70 expression stable over time in B chronic lymphocytic leukaemia?Stéphanie Poulain, Caroline Benard, Agnès Daudignon, et al.
Expert Review of Hematology|October 31, 2023
New developments in the diagnosis and characterization of Waldenström's macroglobulinemiaRamón García-Sanz, Zachary R Hunter, Stéphanie Poulain, et al.
Clinical Case Reports|March 21, 2022
Profuse telangiectasias in an immunocompetent patient misleading presentation revealing a hepatosplenic-Tγδ-cell lymphomaAva Diarra, Benjamin Carpentier, Romain Dubois, et al.
Leukemia Research|April 28, 2009
SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemiaStéphanie Poulain, Marjan Ertault, Xavier Leleu, et al.
Leukemia Research|December 5, 2009
Increased trisomy 12 frequency and a biased IgVH 3-21 gene usage characterize small lymphocytic lymphomaAgnès Daudignon, Stéphanie Poulain, Pierre Morel, et al.
Pageof 5